Thermopylae Holdings Ltd. 4

What Happened Thermopylae Holdings Ltd., listed as a 10% owner of AbCellera Biologics, purchased 177,457 ABCL shares in an open-market/private purchase on February 26, 2026. The filing reports a weighted-average price of $3.27 per share, for a total reported acquisition value of approximately $580,284. This was a purchase (code “P”), which investors often view as a more informative signal than routine sales.

Key Details

• Transaction date: 2026-02-26 (filed with the SEC on 2026-02-27).
• Transaction type/code: Purchase (P).
• Shares acquired: 177,457 shares.
• Reported weighted-average price: $3.27; total reported value ≈ $580,284.
• Price range: the filing notes the shares were bought in multiple trades at prices from $3.19 to $3.40 (see footnote). The reporting person will provide a per-price breakdown to the issuer, shareholders, or SEC staff upon request.
• Shares owned after transaction: Not specified in the provided filing extract.
• Timeliness: Filing appears timely (filed the day after the transaction).

Context This transaction was made by a 10% owner (an institutional holder), not an individual executive. Institutional purchases can reflect portfolio activity rather than insider views of company operations; the filing’s price range indicates the block was accumulated across multiple trades. The footnote clarifies the weighted-average price and offers to disclose the exact per-trade breakdown if requested.